Although cost-effectiveness analysis has not been a formal part of cardiology clinical guidelines until recently, it has "always been the elephant in the room," said Mark Hlatky, MD, professor of health research and policy and professor of cardiovascular medicine at Stanford University.
Although cost-effectiveness analysis has not been a formal part of cardiology clinical guidelines until recently, it has "always been the elephant in the room," said Mark Hlatky, MD, professor of health research and policy and professor of cardiovascular medicine at Stanford University.
Transcript (slightly modified for readability)
How much does cost effectiveness come into consideration when creating and utilizing cardiology clinical guidelines?
Cost-effectiveness analysis has not been formally part of clinical guidelines until just recently. I think it's always been the elephant in the room, where people understood that if it is a costly therapy, we need to take into account whether it was really providing any value. But there was no formal mechanism for doing that. The American College of Cardiology and the American Heart Association recently adopted the idea that we would, in fact, put value grades in for therapies that were judged to be highly effective therapies. We also try to assess their value and incorporate some recognition of the value statement into our guidelines. That's going to happen going forward.
In what ways can cost effectiveness be better utilized when creating new cardiology clinical guidelines?
One of the things that we have an issue for is we are evidence-based and we're not going to be commissioning models of developing things specifically to support the guidelines. So we're going to have to take what's been done already. I think ISPOR and other organizations can be extremely helpful in helping us understand what good studies are and having a way to grade the evidence on this. I think economic evaluations are very complicated sometimes and very difficult to assess and I think we need to figure out ways to make them simpler and to make them credible so they can go and support the guideline.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More